Analysts Turned Bullish on These 10 Stocks on Tuesday

Page 1 of 3

Wall Street is trading on what the Federal Reserve does next, even as analysts keep changing their ratings. The Fed held its key rate steady at its October 27 to 28 meeting, after raising it in September for the first time in three years.

Minutes released on November 18 showed that nearly all officials expect a quarter-point increase in December, and two raised the idea of a half-point move. Wall Street puts the odds of a December hike near 95%, according to the CME Group’s FedWatch tool.

The jump in expectations began on November 10, when a hotter-than-expected October inflation report sent the 2-year Treasury yield up more than 18 basis points, its biggest one-day rise since April 2025, Reuters reported.

Why the Fed May Not Be Done Raising Rates

Fed Governor Christopher Waller backs the larger move. He said inflation is “headed in the wrong direction and it’s spreading out,” and he put core inflation at about a 3.5% annual rate over the past three months, against the Fed’s 2% target. Readers following analysts’ favorite growth names can find more in our ranking of aggressive growth picks from Wall Street analysts.

New York Fed President John Williams disagrees and does not think the situation calls for dramatic action. St. Louis Fed President Alberto Musalem has said the economy will likely need several rate increases before spring 2027, and San Francisco Fed President Mary Daly leans toward more hikes because she worries that companies are passing higher costs on to consumers.

Treasury Yields Back Above 5% Draw Investor Attention

The 10-year Treasury yield touched 5.36% on October 7, its highest level in regular trading since 2002, and it was on pace on November 17 for its 27th close above 5% this year, Bloomberg reported. All of 2007 had 29 such closes. Analysts are still finding value at these levels, as our list of affordable stocks to buy according to Wall Street analysts shows.

JPMorgan Asset Management portfolio manager Priya Misra said yields above 5% reflect a “risk premium due to uncertainty about the Fed.” Dan Carter of Fort Washington Investment Advisors said fixed income offers better risk and reward than it has in some time, and that the stock rally since 2023 may push many portfolios to rebalance toward bonds. The pressure is also showing up in housing: 30-year mortgage rates have stayed above 7% since mid-September, and Ian Lyngen of BMO Capital Markets said the effect on real estate has been to freeze activity.

Analysts Turned Bullish on These 10 Stocks on Tuesday

Our Methodology

To compile this list, we reviewed analyst rating upgrades and price target increases announced on Tuesday, November 17, 2026. We selected 10 stocks that are listed in the U.S. and had an analyst call that day, and ranked them in ascending order of their average upside potential. Upside is based on analysts’ average price target compared with each stock’s share price, as of November 18.

At Insider Monkey, we are obsessed with what hedge funds do. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 612% since May 2014, beating its benchmark by 375 percentage points (see more details here).

Analysts Turned Bullish on These 10 Stocks on Tuesday

10. Medtronic (NYSE:MDT)

Average Upside Potential: 5%

Piper Sandler analyst Matt O’Brien upgraded Medtronic to Overweight from Neutral on November 17 and raised his price target to $120 from $85. He expects growth drivers to push revenue above consensus, with cardiac ablation leading in the near term and an investor meeting set for December 11.

Medtronic makes device-based therapies for heart, brain and surgical care. In the first quarter of fiscal 2027, sales of its Cardiac Ablation Solutions products grew 88%, the Cardiovascular portfolio grew 18.9%, and the company raised its fiscal 2027 organic revenue growth guidance by 50 basis points. Non-GAAP earnings per share also rose from a year earlier, and the quarter included an extra fiscal week that added about $570 million in revenue. On November 16, Medtronic announced plans to acquire Contego Medical, and on November 17 it said the FDA had cleared its Hugo robotic system for general surgery.

Medtronic is expected to report its next quarterly results on November 24, and analysts expect earnings of $1.33 per share. We examined how Medtronic’s modest valuation lines up with its improving growth outlook in a separate piece.

9. United Natural Foods (NYSE:UNFI)

Average Upside Potential: 6%

Goldman Sachs analyst Leah Jordan upgraded United Natural Foods to Buy from Neutral on November 17 and raised her price target to $60 from $49. She pointed to the company’s outsized exposure to the higher-growth natural and organic category.

United Natural Foods distributes natural, organic and specialty foods to grocery stores and other retailers. Profit has grown faster than sales. In the fourth quarter of fiscal 2026, adjusted earnings before interest, taxes, depreciation and amortization (EBITDA) rose 48.3% while net sales fell from a year earlier. That leaves the bull case resting on profit growth continuing without much help from the top line. For fiscal 2027, the company guided to adjusted EBITDA above the $701 million it earned in fiscal 2026. It also generated $323 million of free cash flow in fiscal 2026 and announced a new share buyback.

United Natural Foods is expected to report its next quarterly results on December 8, and analysts expect earnings of $0.66 per share. Our earlier coverage of how the distributor called a bottom and guided for growth again has more on that outlook.

Page 1 of 3